Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University ...

Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...

Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial The data ...

CHARLOTTESVILLE, Va., Sept. 4, 2025 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) ...

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system Provided by PR Newswire Sep 4, 2025, 11:00:00 AM RIVANNA awarded $2.21 million NIH grant to ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine ...

DALLAS, Jan. 24, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the ...

DALLAS - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotech company with a current market capitalization of approximately $31 million, has unveiled promising preclinical data for its drug ...